在减重药竞争日益加剧的背景下，跨国制药巨头纷纷聚焦中国的减重药资产。 2月25日亚太股市开盘后，联邦制药（3933.HK）股价一路上涨，下午股价一度飙涨超过7%。 值得关注的是，去年3月，诺和诺德与联邦制药就UBT251达成了授权协议，首付款2亿美元，潜在交易 总额高达20亿美元。 UBT251是一款在研的针对GLP-1/GIP/GCG三重靶点的新一代减重药，有望较目前礼来的双靶点GLP-1 减重药获得更好的减重效果。 去年7月，石药集团以20.75亿美元将口服小分子GLP-1受体激动剂授权给Madrigal公司；今年年初，石 药集团又将另一款双靶点的新一代减重注射药授权给阿斯利康。 目前，包括恒瑞医药、翰森制药、诚益生物在内的本土药企的GLP-1类药物都已经通过对外授权的方式 实现出海。 前一日，联邦制药公布了新一代三重靶点减重药UBT251中国的一项中期临床试验数据，该注射液每周 给药一次，在连续给药24周后，试验药组平均减重达19.7%，安慰剂组仅为2%。 一位未参与临床试验的内分泌专家对第一财经记者表示，这一试验结果"非常不错"，展示了中国研发的 新一代减重药的潜力。 这一积极的临床数据也为急需利好消 ...

相关单位已对不合格产品采取了必要的控制措施，依法对违法行为进行查处。 北京市药品监督管理局关于发布2026年第一期药品质量安全信息的通告 北京市药品监督管理局按要求组织对药品生产、经营、使用环节开展了监督抽检，现将抽检发现不符合规定的药品予以通告（详见附件）。 特此通告。 北京市药品监督管理局 2026年2月13日 不符合规定药品名单 | 药品 | 标示药品上 | | | | 抽 | | | 检验 | 不符合 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 市许可持有 | 标示生产企业 | 批号 | 规格 | 样 | 检品来源 | 检验依据 | | | 检验机构 | 备注 | | 名称 | 人 | | | | 环 | | | 结论 | 规定项 | | | | | | | | | 节 | | | | 目 | | | | 款冬 | | 湖北道地药材 | | | 经 营 | 北京百药堂好药 | | 不符 | 性状、 | 北京市丰台区食 | 生产企业 | | | / | | 240304 | 中药饮 ...

万思瀚薪酬暴涨也源于公司长期绩效计划的高额兑现。2023至2025年期间，万思瀚的长期激励计划兑现 率高达188%，价值1730万瑞士法郎。过去三年间，诺华股价从2022年底的约90美元飙升至2026年初的 近160美元，总股东回报率高达84%，在15家全球医疗保健同行企业中排名第二。 另一家瑞士制药巨头罗氏CEO托马斯·施尼克尔（Thomas Schinecker）在2025年总共获得了1020万瑞士 法郎（约合9075万元人民币）的薪酬。 2026.02.25 本文字数：1036，阅读时长大约2分钟 作者 |第一财经 钱童心 当地时间2月24日，阿斯利康的一份备案文件显示，该公司CEO苏博科（Pacal Soriot）2025年的薪酬增 至1770万英镑（约合1.64亿元人民币），跻身英国富时100指数中薪酬最高的高管之列。 阿斯利康也是伦敦证交所上市公司中市值最高的企业，最新市值超过3200亿美元（约合2.2万亿元人民 币）。受益于公司强劲的业绩和股价表现，2025年，苏博科获得了高达430万英镑的年度奖金，较2024 年的水平增长约22%。 截至本月，欧洲制药公司高管2025年度年薪陆续披露。近日，瑞 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [7] Core Insights - The report highlights the continuous upgrading of policies in the Heilongjiang biomanufacturing industry, focusing on innovative traditional Chinese medicine and innovative medical devices [4] - The report emphasizes the significant revisions to the Drug Administration Law, which provides institutional support for pharmaceutical innovation and high-quality development [4] - The report identifies three major transformations in China's innovative drug business development (BD) in 2026: technology output combined with product authorization, platform cooperation, and global parallel innovation [8] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -7.06% compared to the CSI 300 index, with an absolute return of 11.53% [3] Investment Highlights - The report notes that BD transactions in the pharmaceutical sector are focused on unmet clinical needs, technological differentiation, and global value [6] - Key areas of focus include oncology therapies such as dual antibodies, ADCs, and TCE combinations, with significant financial agreements highlighted, such as a $650 million upfront payment for a PD-1/VEGF dual antibody [6] - The metabolic disease sector is centered on long-acting GLP-1 and small nucleic acid precision therapies, with notable collaborations resulting in substantial upfront payments and potential total amounts [6] Company-Specific Developments - Companies like Andover Pharmaceuticals and Frontier Biotech have secured significant collaborations with major pharmaceutical firms, indicating a trend towards platform-based cooperation and technology output [7] - Specific collaborations include a $1.05 billion deal for a CTLA-4 inhibitor and a $400 million agreement for small nucleic acid drugs, showcasing the growing interest in innovative therapies [7] - The report suggests monitoring companies such as Rebio Biotech and WuXi AppTec for their advancements in small nucleic acids and platform capabilities [8]

Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations to return to an upward cycle by 2026 and benefit from the launch of innovative oncology and metabolic products starting in 2027 [1] Group 1: Revenue and Profit Outlook - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to gradually enhance the company's profits over the next 3-5 years [1] - The firm believes that upfront payments and milestone revenues will provide sustainable recurring income for the company, leading to an upward revision of the revenue forecast for authorized products post-2027 [1] Group 2: R&D and Collaboration - CSPC Pharmaceutical Group has achieved seven external collaboration deals in the past two years, with total upfront payments of $1.71 billion and potential milestone revenues exceeding $30 billion [2] - The company has partnered with AstraZeneca three times, highlighting its R&D platform's global influence and value [2] - The firm is optimistic about CSPC's ability to generate regular income through milestone sales and net revenue sharing throughout the drug lifecycle [2] Group 3: Pipeline and Technology - CSPC's small nucleic acid platform has a broad layout, targeting popular liver delivery points such as PCSK9, AGT, and ANGPTL3, and is ahead of domestic peers in development [3] - The company has applied for patents related to lipid delivery and specific siRNA treatments, indicating potential advancements in neurological and ocular delivery technologies [3] - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential for best-in-class efficacy and safety [4] Group 4: Clinical Developments - The company has initiated a Phase III clinical trial for SYS6010 in China for first-line treatment of non-small cell lung cancer (NSCLC) and plans to advance global Phase III trials [4] - CSPC's in vivo CAR-T product, SYS6055, has received clinical approval in China, representing the first in vivo CAR-T product approved domestically, with potential advantages in cost and accessibility [4] Group 5: Financial Projections - The firm has adjusted revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, 28.9 billion, and 30.6 billion respectively, reflecting changes in the recognition of upfront payments [5] - The net profit forecasts for FY25, FY26, and FY27 have been revised to RMB 4.4 billion, 4.6 billion, and 5.3 billion respectively [6]

Group 1 - The core point of the article is that 德琪医药-B (06996) has seen a stock increase of over 6%, currently trading at 3.66 HKD with a transaction volume of 13.32 million HKD [1] - The company announced a clinical collaboration agreement with 君实生物 to explore the combined treatment potential of its ATG-037 (oral CD73 small molecule inhibitor) and 君实生物's JS207 (anti-PD-1/VEGF bispecific antibody) in cancer patients in mainland China [1] - The collaboration aims to validate the synergistic effects of the two innovative drugs and to overcome the current efficacy ceiling of immunotherapy through a "triple-axis" strategy of "immunotherapy + anti-angiogenesis + adenosine inhibition," ultimately aiming to significantly extend overall survival (OS) for cancer patients [1]

Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations of returning to an upward cycle by 2026 and benefiting from the launch of oncology and metabolic innovative products starting in 2027 [1] Group 1: Financial Projections - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to enhance the company's profits over the next 3-5 years [1] - Haitong International has adjusted the revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, RMB 28.9 billion, and RMB 30.6 billion respectively [5] - The net profit forecasts for FY25, FY26, and FY27 have been adjusted to RMB 4.4 billion, RMB 4.6 billion, and RMB 5.3 billion respectively [6] Group 2: Research and Development Capabilities - CSPC Pharmaceutical Group has completed seven external cooperation transactions in the past two years, with total upfront payments of $1.71 billion and potential milestone amounts exceeding $30 billion [1] - The company has established a strong research and development platform, evidenced by collaborations with AstraZeneca, indicating its global influence and value [1] - The company is recognized for its small nucleic acid platform, which covers popular liver delivery targets and is ahead of domestic peers in development [2] Group 3: Product Pipeline and Market Potential - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential as a best-in-class product [3] - The company has initiated a Phase III clinical trial for SYS6010 in China and plans to advance global Phase III trials within the year [3] - CSPC has received the first clinical approval in China for its in vivo CAR-T product, SYS6055, which is expected to have advantages in cost, accessibility, and immediacy compared to traditional CAR-T products [4]

Core Viewpoint - The collaboration between Deqi Pharmaceutical and Junshi Biosciences aims to explore the synergistic potential of their respective drugs, ATG-037 and JS207, in treating tumor patients in mainland China, particularly in the context of overcoming resistance to immune checkpoint inhibitors [1] Group 1: Company Developments - Deqi Pharmaceutical's stock rose by 6.4%, reaching HKD 3.66, with a trading volume of HKD 13.326 million [1] - The company announced a clinical collaboration agreement with Junshi Biosciences to jointly investigate the combination therapy of ATG-037, an oral CD73 small molecule inhibitor, and JS207, a dual-specific antibody targeting PD-1/VEGF [1] Group 2: Industry Context - The collaboration addresses a significant clinical challenge where resistance to immune checkpoint inhibitors (CPI) has become prevalent [1] - ATG-037 has demonstrated strong potential in reversing resistance in Phase I trials when used in combination with CPIs [1] - The partnership aims to validate the synergistic effects of the two innovative drugs and seeks to extend overall survival (OS) for cancer patients through a "triple-axis" strategy involving "immunotherapy + anti-angiogenesis + adenosine inhibition" [1]

Group 1 - In 2025, AstraZeneca's CEO Pascal Soriot received a total compensation of £17.7 million (approximately 164 million RMB), making him one of the highest-paid executives in the FTSE 100 index [1] - AstraZeneca's market capitalization exceeds $320 billion (approximately 2.2 trillion RMB), making it the highest-valued company listed on the London Stock Exchange [1] - Soriot's annual bonus reached £4.3 million in 2025, reflecting a 22% increase compared to 2024 [1] Group 2 - Novartis CEO Vas Narasimhan's compensation for 2025 is reported at 24.9 million Swiss francs (approximately 22 million RMB), marking a 30% increase from 2024 and the highest since he took office in 2018 [2] - Narasimhan's long-term incentive plan had a payout rate of 188% during the 2023-2025 period, valued at 17.3 million Swiss francs [2] - Roche's CEO Thomas Schinecker received a total compensation of 10.2 million Swiss francs (approximately 9.1 million RMB) for 2025 [2] Group 3 - Sanofi's CEO Paul Hudson received a total compensation of €10.9 million (approximately 8.8 million RMB) for 2025, but he will not receive performance bonuses for the 2026 fiscal year as he stepped down on February 17, 2025 [2] - Novo Nordisk's new CEO Maziar Mike Doustdar earned 20.7 million Danish kroner (approximately 2.2 million RMB) during his first few months in office [3] - The previous CEO Lars Fruergaard Jorgensen received nearly $20 million (approximately 137 million RMB) in total compensation for 2025, which included a severance payment of $6.82 million [3] Group 4 - The annual salaries of U.S. pharmaceutical executives for 2025 have not yet been disclosed, but historically, they tend to be higher than those of European pharmaceutical executives [3] - In 2024, Eli Lilly's CEO David Ricks had the highest salary in the global pharmaceutical industry at $29.2 million (approximately 200 million RMB) [3] - Pfizer's CEO Albert Bourla also had a significant salary of $24.6 million (approximately 170 million RMB), ranking second in the industry [3]

消息面上，2月23日，基石药业宣布，其PD-L1抗体舒格利单抗针对III期非小细胞肺癌(NSCLC)的新适 应症，已正式取得英国药品和医疗保健用品管理局(MHRA)的批准。此次获批是该适应症继2024年7月 获得欧盟委员会(EC)许可之后，在欧洲核心市场取得的又一关键突破。 此外，基石药业核心资产CS2009用于晚期实体瘤的II期临床试验IND申请近期获得FDA批准。 CS2009(PD-1/VEGF/CTLA-4三特异性抗体)用于晚期实体瘤的II期新药临床试验申请(IND)获美国食品药 品监督管理局(FDA)批准，标志着这一创新免疫疗法的全球开发取得重要进展。 基石药业-B(02616)再涨超6%，月内累计涨幅已超25%。截至发稿，涨5.03%，报6.68港元，成交额1.02 亿港元。 ...